Sensus Healthcare Intrinsic Value Calculation – SENSUS HEALTHCARE Reports 62.5% Decrease in Revenue For Q2 FY2023
August 26, 2023
🌥️Earnings Overview
SENSUS ($NASDAQ:SRTS):
Analysis – Sensus Healthcare Intrinsic Value Calculation
GoodWhale’s financial analysis of SENSUS HEALTHCARE shows that the fair value of its share is around $6.8. This value was calculated using our proprietary Valuation Line, which takes into account the company’s profitability, growth potential, financials, and other market factors. At present, the stock is trading at $2.7, which represents an undervaluation of 60.4%. This presents a great opportunity for those looking to invest in SENSUS HEALTHCARE. The company has a strong financial position and growth potential, making it an attractive investment option. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Sensus Healthcare. More…
| Total Revenues | Net Income | Net Margin |
| 30.06 | 2.38 | 7.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sensus Healthcare. More…
| Operations | Investing | Financing |
| -10.49 | 14.84 | -2.43 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sensus Healthcare. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 52.02 | 6.01 | 2.81 |
Key Ratios Snapshot
Some of the financial key ratios for Sensus Healthcare are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 20.4% | – | 8.7% |
| FCF Margin | ROE | ROA |
| -35.9% | 3.5% | 3.2% |
Peers
The company’s products include radiation therapy systems and products for treating cancer with lasers. The company’s products are used by hospitals, clinics, and physicians. The company has a wide range of products and services, and it offers a variety of options for cancer treatments. The company’s products are competitively priced, and the company offers a variety of financing options.
– Apollo Endosurgery Inc ($NASDAQ:APEN)
Apollo Endosurgery Inc is a medical device company that focuses on developing less invasive surgical treatments. As of 2022, the company has a market capitalization of 271.04 million and a return on equity of -42.15%. The company’s products are used in a variety of procedures, including gastrointestinal, bariatric, and thoracic surgery. Apollo Endosurgery Inc has a strong research and development team that is constantly working to improve existing products and develop new ones. The company’s products are sold in over 60 countries around the world.
– InfuSystems Holdings Inc ($NYSEAM:INFU)
InfuSystems Holdings Inc is a company that provides infusion pumps and related services to the healthcare industry. The company has a market cap of 177.64M as of 2022 and a Return on Equity of 2.81%. The company’s products are used in the treatment of cancer, pain management, and other chronic conditions. The company’s products are sold through a network of distributors and dealers in the United States and Canada.
– Bone Biologics Corp ($NASDAQ:BBLG)
Bone Biologics Corp is a biotechnology company that focuses on the development of novel therapeutics for the treatment of bone diseases. The company’s market cap is 3.99M as of 2022. Its ROE is -16.65%. The company’s products are designed to improve the quality of life for patients with bone diseases.
Summary
SENSUS HEALTHCARE reported total revenue of USD 4.5 million for the second quarter of FY2023 ending on June 30 2023, a decrease of 62.5% compared to the same period last year. Net income for this period was USD -0.38 million, down from 3.52 million the year prior. This news caused the stock price to drop significantly, making SENSUS HEALTHCARE an investment opportunity that should be approached with caution.
While the company has a strong presence in the healthcare technology sector, investors should consider the risks associated with investing in SENSUS HEALTHCARE given the company’s recent financial performance. It may be wise to wait until the company can turn around its profitability before investing.
